DOCSLIB.ORG

Abstract Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstract Book Abstract book Livre des résumés Secrétariat général : 4 avenue de l’Observatoire - 75270 Paris Cedex 06 Tél : +33 (0)1 43 25 54 49 Fax : +33 (0)1 43 29 45 85 Courriel : [email protected] http://acadpharm.org/ ICRAPHE 2016 Under the High Patronage Under the Honorary Sponsorship of Ségolène ROYAL, Minister of Environment, Energy and Sea Marisol TOURAINE, Minister for Social Affairs and Health Cloître des Cordeliers - 21 rue de l’École de Médecine 75006 PARIS P ROGRAM 8 S EPTEMBER 8h30 Reception 9h00 Opening session Ségolène ROYAL, Minister of Environment, Energy and Sea (to be confirmed) Benoît VALLET, General Director of Health, Ministry for Social Affairs and Health Claude MONNERET, President of the French Academy of Pharmaceutical Sciences 9h30 Plenary conference by Maria NEIRA, Department of Public Health, Environmental and Social Determinants of Health, WHO 10h00 Oral Session “Hazard identification - adverse effects in human and environment” “Ecotoxicological characterization of pharmaceuticals during regulatory assessments: state of the art, options for improvement” Speaker and Moderator, Dr Thomas BACKHAUS, Professor for Ecotoxicology and Chemical Risk Assessment at the University of Gothenburg (Sweden) and leader of the Center for Future Risk Assessment and Management Strategies Communications: 10h40: Impact of psychotropic pharmaceuticals on freshwater organisms, J.-Y. MAZZITELLI, Biochimie et Toxicologie des Substances Bioactives (BTSB, EA7417)-Institut National Universitaire Champollion, Albi, France 1 11h00: Toxic and genotoxic effects of the residues of anticancer drugs in aquatic organisms, M. FILIPIC, Department of Genetic Toxicology and Cancer Biology-National Institute of Biology (NIB) - Ljubljana, Slovenia 11h20: Analysis of toxicological effects of atenolol, caffeine, lidocaine and oxytetracycline on Raphidocelis subcapitata and Chlorella vulgaris algae, Z. PROCOPIO, Glasgow Caledonian University, Glasgow, United Kingdom 11h40: Combination effects of endocrine active pharmaceuticals in wastewaters using the Calux reporter-gene assay, H. BIELAK, IWW Water Centre, Mülheim, Germany 12h00: Mixtures effect of antibiotics on soil microbial nitrogen processes, V. DAVID, AgroParisTech, INRA- ECOSYS (Ecologie fonctionnelle et éco-toxicologie des agro- écosystèmes), Versailles, France 12h30 pm Lunch BREAK AND POSTER EXHIBITION 2h00 pm Oral Session “Exposure assessment” “Pharmaceuticals as environmental contaminants: analysis and levels in the environment” Speaker and Moderator, Dr Ettore ZUCCATO, Department of Environmental Health Sciences-Mario Negri Institute for Pharmacological Research, Milan, Italy Communications: 2h40 pm: Innovation in effect monitoring of pharmaceuticals - in vitro, in vivo, in environment, J. BACHMANN, Federal Environment Agency (UBA), Dessaud-Roβlau, Germany 3h00 pm: New rapid cell-based assays for β-blocker and nonsteroidal anti-inflammatory drug determination in wastewater effluents, F. FREY, Steinbeis Transfer Center for Applied Biological Chemistry, Mannheim, Germany 3h20 pm : A novel approach for determining the uptake of pharmaceuticals and personal care products from sediment at the landscape scale, L. CARTER, Environment Department, University of York, York, United Kingdom 3h40 pm BREAK AND POSTER EXHIBITION 4h10 pm: Next-Generation Sequencing to highlight community changes in river biofilms linked to pharmaceutical loads from a wastewater treatment plant, T. CHONOVA, INRA, UMR CARRTEL, Thonon-les-Bains, France 4h30 pm: Prioritisation of veterinary pharmaceuticals prior to a monitoring campaign: Case of Brittany, an intensive husbandry area, L. CHARUAUD, École des Hautes Études en santé publique (EHESP)-Laboratoire d'Étude et de Recherche en Environnement et Santé (LERES), Rennes, France 5h00 pm End of the first day: closing remarks 7h30 pm Gala Dinner 2 9 S EPTEMBER 9h00 Oral Session “Risk assessment” “Pharmaceuticals in the environment: are they posing unacceptable risks?” Speaker and Moderator, Alistair BOXALL, Professor of Environmental Science at the University of York, York, United Kingdom Communications: 9h40: Health risk assessment of pharmaceuticals in drinking water in France, P. PANETIER, ANSES-Agence nationale de Sécurité sanitaire de l’Alimentation, de l’Environnement et du Travail, Paris, France 10h00: Assessing effects of pharmaceuticals on aquatic ecosystems, I. ROESSINK, Alterra, Wageningen, Netherlands 10h20: Occurrence of pharmaceuticals in hospital wastewaters and assessment of their associated environmental risk and hazard: a Spanish case study, M. LOPEZ DE ALDA, Department of Environmental Chemistry-Institute of Environmental Assessment and Water Research (IDAEA), Barcelona, Spain 10h40 BREAK AND POSTER EXHIBITION 11h10: Critical evaluation of different inputs for the estimation of pharmaceuticals exposure seeking an improved environmental risk assessment, A. PEREIRA, University of Coimbra, Faculty of Pharmacy-LAQV, REQUIMTE, Group of Bromatology, Pharmacognosy and Analytical Sciences, Coimbra, Portugal 11h30: Human and ecotoxicological potential impact of pharmaceutical and personal care products from USEtoxTM life cycle impact assessment characterization factors, R. IRUSTA- MATA, Department of Chemical Engineering and Environmental Technology, University of Valladolid, Valladolid, Spain 11h50: People thinking about pharmaceutical risk – health and environment: evidence from noPILLS, P. TEEDON, Glasgow Caledonian University, Glasgow, United-Kingdom 12h10: Investigation of the implications for Ireland of emerging standards on pharmaceuticals in receiving waters, N. ROWAN, Bioscience Research Institute-Athlone Institute of Technology (AIT), Athlone, Ireland 12h30 pm Lunch BREAK AND POSTER EXHIBITION 2h30 pm Session “Risk management” Speaker and Moderator, Dr Klaus KÜMMERER, Professor of Sustainable Chemistry and Material Resources-Institute of Sustainable and Environmental Chemistry-Leuphana University, Lüneburg, Germany 3h00 pm: Round table – Maria NEIRA (Department of Public Health, Environmental and Social Determinants of Health, World Health Organisation) ; Jean-Marc VIDAL 3 (Specialised Scientific disciplines Department, European Medicines Agency, London, United Kingdom); Shane A. SNYDER (Department of Chemical and Environmental Engineering, University of Arizona, Tucson, USA); Miquel PARAIRA FAUS (Aiguës de Barcelona and AQUADOM (Agbar group), Barcelona, Spain); Sandrine SOURISSEAU (Environment and Health Department-VEOLIA Environnement Recherche et Innovation, Poissy, France) 5h00 pm closing remarks 4 ICRAPHE 2016 Sous les Hauts Patronages de Ségolène ROYAL, Ministre de l’Environnement, de l’Énergie et de la Mer Marisol TOURAINE, Ministre des Affaires Sociales et de la Santé Cloître des Cordeliers - 21 rue de l’École de Médecine 75006 PARIS P ROGRAMME 8 S EPTEMBRE 8h30 Accueil 9h00 Session d’ouverture Ségolène ROYAL, Ministre de l’Environnement, de l’Énergie et de la Mer (à confirmer) Benoît VALLET, Directeur Général de la Santé, Ministère des Affaires Sociales et de la Santé Claude MONNERET, Président de l’Académie nationale de Pharmacie 9h30 Conférence plénière : Maria NEIRA, Directeur du département Santé Publique et Environnement - Organisation Mondiale de la Santé 10h00 Session « Identification des dangers, effets néfastes chez l’homme et sur l’environnement » « Caractérisation écotoxicologique des résidus de médicaments dans le cadre de l’évaluation réglementaire : état de l’art, options d’amélioration » Conférencier et modérateur Dr Thomas BACKHAUS, Professeur d’écotoxicologie et d’estimation des risques chimiques à l’Université de Gothenburg (Suède), Directeur du « Center for Future Risk Assessment and Management Strategies » Communications : 10h40: Impact of psychotropic pharmaceuticals on freshwater organisms, J.-Y. MAZZITELLI, Biochimie et Toxicologie des Substances Bioactives (BTSB, EA7417)-Institut National Universitaire Champollion, Albi, France 11h00: Toxic and genotoxic effects of the residues of anticancer drugs in aquatic organisms, M. FILIPIC, Department of Genetic Toxicology and Cancer Biology-National Institute of Biology (NIB), Ljubljana, Slovenia 5 11h20: Analysis of toxicological effects of atenolol, caffeine, lidocaine and oxytetracycline on Raphidocelis subcapitata and Chlorella vulgaris algae, Z. PROCOPIO, Glasgow Caledonian University, Glasgow, United Kingdom 11h40: Combination effects of endocrine active pharmaceuticals in wastewaters using the Calux reporter-gene assay, H. BIELAK, IWW Water Centre, Mülheim, Germany 12h00: Mixtures effect of antibiotics on soil microbial nitrogen processes, V. DAVID, AgroParisTech, INRA- ECOSYS (Ecologie fonctionnelle et éco-toxicologie des agro- écosystèmes), Versailles, France 12h30 Déjeuner PAUSE ET VISITE DES POSTERS 14h00 Session « Estimation des expositions » « Les résidus de médicaments en tant que contaminants de l’environnement : analyse et niveaux dans l’environnement » Conférencier et modérateur, Dr Ettore ZUCCATO, Department of Environmental Health Sciences - Mario Negri Institute for Pharmacological Research, Milan, Italie Communications: 14h40: Innovation in effect monitoring of pharmaceuticals - in vitro, in vivo, in environment, J. BACHMANN, Federal Environment Agency (UBA), Dessaud-Roβlau, Germany 15h00: New rapid cell-based assays for β-blocker and nonsteroidal anti-inflammatory drug determination in wastewater effluents, F. FREY, Steinbeis Transfer Center for Applied Biological Chemistry, Mannheim, Germany 15h20 : A novel approach for determining
Load more

Recommended publications
  • Alzheimer's Disease, a Decade of Treatment: What Have We Learned?
    A Critical Look at Medication Dementia: Alzheimer’s Disease Management Issues in Alzheimer’s Disease R.Ron Finley, B.S. Pharm., R.Ph,CGP Lecturer (Emeritus) and Assistant Clinical Professor, UCSF School of Pharmacy Clinical Pharmacist, UCSF Memory and Aging Center- Alzheimer’s Research Center Educational Objectives Disclosures 1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia. Pfizer Speakers Bureau 2. Name three common side effects of atypical antipsychotic Forest Speakers Bureau drugs. Novartis Speakers Bureau 3. Construct a pharmacological treatment plan for a 77-year-old Rx Consultant Associate Editor patient diagnosed with Alzheimer’s disease and hallucinations. WindChime Consultant 4. Describe the role for antipsychotic, antidepressant, mood HGA HealthCare Consultant stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease. Elder Care Specialist Consultant 5. Cite three potential drug or disease interactions with cholinesterase inhibitors. The Many Faces of Dementia Risk Factors Linked to AD Alzheimer’s Disease Over 65 years of age and increases Vascular: Multi-infarct with age FrontalTemporal Lobe dementia ( FTD) and female Pick’s disease Head injury Lewy Body Dementia Progressive Supranuclear Palsy Factors associated with DM, HTN, CVD Corticobasal Degeneration Genetic: family history, specific Primary Progressive Aphasia chromosome mutations Huntington’s disease
    [Show full text]
  • Synthetic Drugs
    Comprehensive and Confident Identification of Narcotics, Steroids and Pharmaceuticals in Urine David E. Alonso1, Petra Gerhards2, Charles Lyle1 and Joe Binkley1 | 1LECO Corporation, St. Joseph, MI; 2LECO European LSCA Centre, Moenchengladbach, Germany Introduction Experimental Sample A (Traditional Drugs) Sample B (Synthetic Drugs) Monitoring of patients in hospitals and clinics has traditionally relied on Samples Representative Compounds Representative Compounds targeted methods of analysis. These screening methods are not Peak # Name Formula R.T. (s) Area Similarity Mass Delta (mDa) MA (ppm) 1 Creatinine ME C5H9N3O 210 1326229 800 -0.05 -0.43 • Obtained from a collaborating European hospital 3.5e6 3.0e6 Peak # Name Formula R.T. (s) Area Similarity 2 o-Ethynylaniline C8H7N 219 167436 893 0.07 0.63 1 Indole C8H7N 213 2744171 917 comprehensive and result in an incomplete picture of a patient’s 3 2-Methoxy-4-vinylphenol C H O 223 65764 805 0.11 0.73 52 patient monitoring samples 9 10 2 2 Creatinine ME C5H9N3O 216 613318 651 • 2.5e6 4 Nicotine C10H14N2 234 3249121 898 -0.21 -1.29 3 Pyridine, 2-(1-methyl-2-pyrrolidinyl)- C10H14N2 230 24869771 899 activities. Gas chromatography high resolution time-of-flight mass 3.0e6 5 Hordenin C10H15NO 274 949734 775 -0.14 -0.84 4 Parabanic acid, 1-methyl- C4H4N2O3 233 434278 764 Sample preparation 5 Cotinine C10H12N2O 336 27810908 918 • 6 Methylecgonine C10H17NO3 276 104640 835 -0.22 -1.1 spectrometry (GC-HRT) provides a fast and convenient method for 2.0e6 5 6 Caffeine C8H10N4O2 371 3753598 797 2.5e6 7 4-(3-Pyridyl-tetrahydrofuran-2-one C9H9NO2 313 93817 849 -0.11 -0.68 3,4 7 1-methyl-7H-xanthine C6H6N4O2 437 4868196 850 analysis of urine samples.
    [Show full text]
  • THE POSSIBLE ROLE of LEUKOCYTE-GENERATED Reactrve INTERMEDIATES in the DRUG-INDUCED Agrancnocytosis
    THE POSSIBLE ROLE OF LEUKOCYTE-GENERATED REACTrVE INTERMEDIATES IN THE DRUG-INDUCED AGRANCnOCYTOSIS Zhao Chao Liu A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Faculty of Pharmacy University of Toronto O Copyright by Zhao Chao Liu 1997 National Library Bibliothèque nationale (*m of Canada du Canada Acquisitions and Acquisitions et Bibliographic Services services bibliographiques 395 Wellington Street 395, rue Wellington Ottawa ON K1A ON4 Ottawa ON KIA ON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant a la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or seil reproduire, prêter, distribuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la fome de microfiche/£ïlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. ABSTRACT Ticlopidine and clczapine are associated with relatively high incidences of agranulocytosis. 5-aminosalicylic acid (5-ASA) is an agent widely used in the treatment of inflammatory bowel disease. It has been demonstrated that many drugs associated with drug-induced agranulocytosis or dmg-induced lupus are oxidized by activated neutrophils to reactive intermediates, by the combination of myeloperoxidase (MPO), hydrogen peroxide and chloride ion, or simply by hypochlorous acid (HOCI).
    [Show full text]
  • And Radiation Therapy Sensitizing Strategies in Tumours with Focus on Effects of Phenothiazines on Dna Damage Response Signalling
    From DEPARTMENT OF ONCOLOGY-PATHOLOGY Karolinska Institutet, Stockholm, Sweden ANALYSIS AND CHARACTERIZATION OF CHEMO- AND RADIATION THERAPY SENSITIZING STRATEGIES IN TUMOURS WITH FOCUS ON EFFECTS OF PHENOTHIAZINES ON DNA DAMAGE RESPONSE SIGNALLING Katarzyna Zielinska-Chomej Stockholm 2015 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by E-Print AB 2015 © Katarzyna Zielinska-Chomej, 2015 ISBN 978-91-7549-898-0 Analysis and characterization of chemo- and radiation therapy sensitizing strategies in tumours with focus on effects of phenothiazines on DNA damage response signalling THESIS FOR DOCTORAL DEGREE (Ph.D.) Dept of Oncology-Pathology, Cancer Center Karolinska (CCK) Lecture Hall, R8:00, Karolinska University Hospital, Stockholm Friday, the 16th of October, 2015, at 09:00 By Katarzyna Zielinska-Chomej Principal Supervisor: Opponent: Kristina Viktorsson, PhD Associate Prof Karin Roberg, MD, PhD Karolinska Institutet Linköping University Department of Oncology-Pathology Department of Clinical and Experimental Medicine Division of Otorhinolaryngology Co-supervisor(s): Petra Hååg, PhD Examination Board: Karolinska Institutet Associate Prof Marika Nestor, MD, PhD Department of Oncology-Pathology Uppsala University Department of Surgical Sciences, Otolaryngology and Head & Neck Surgery and Department of Professor Rolf Lewensohn, MD, PhD Immunology, Genetics and Pathology Karolinska Institutet Division of Biomedical Radiation Sciences Department of Oncology-Pathology
    [Show full text]
  • Clozapine-Induced Toxicity Via Induction of Oxidative Stress and Mitochondrial Dysfunction in Human Blood Lymphocytes and Protecting Role of L-Carnitine
    Original Research Article 2020;3(1):e9 Clozapine-induced Toxicity via Induction of Oxidative Stress and Mitochondrial Dysfunction in Human Blood Lymphocytes and Protecting role of L-Carnitine a b c,d a b* Ahmad Salimi , Farnaz Imani , Zhaleh Jamali , Negar Ahvar , Jalal Pourahmad a. Department of Pharmacology and Toxicology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran. b. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. c. Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. d. Department of Addiction Studies, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. Article Info: Abstract: Received: September 2020 Clozapine is a useful antipsychotic drug but with serious, life threatening toxicity Accepted: September 2020 effects. The aim of this study is to assess the direct cytotoxicity effect of clozapine Published online: (CLZ) on human blood lymphocytes and investigate the protective effect of L‐carnitine October 2020 (LC) against clozapine‐induced cytotoxicity. Clozapine at 70 μM concentration induced cytotoxicity following 12 h. The Clozapine induced cytotoxicity was associated with intracellular reactive oxygen species (ROS) generation, mitochondrial * Corresponding Author: membrane potential (MMP) collapse, lysosomal membrane injury, lipid peroxidation, Jalal Pourahmad Email: and depletion of glutathione (GSH) and raising of oxidized glutathione (GSSG). We [email protected] showed that LC (1 mM) has a beneficial cytoprotective effect against clozapine- induced toxicity. Summery, clozapine causes organelles damages and triggers oxidative stress in lymphocytes. These data suggest that using of L‐carnitine could be useful for prevention and treatment of clozapine toxicity.
    [Show full text]
  • Drug Distribution Into Peripheral Nerve S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/03/06/jpet.117.245613.DC1 1521-0103/365/2/336–345$35.00 https://doi.org/10.1124/jpet.117.245613 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 365:336–345, May 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Drug Distribution into Peripheral Nerve s Houfu Liu, Yan Chen, Liang Huang, Xueying Sun, Tingting Fu, Shengqian Wu, Xiaoyan Zhu, Wei Zhen, Jihong Liu, Gang Lu, Wei Cai, Ting Yang, Wandong Zhang, Xiaohong Yu, Zehong Wan, Jianfei Wang, Scott G. Summerfield, Kelly Dong, and Georg C. Terstappen Department of Mechanistic Safety and Disposition (H.L., X.S., T.F., S.W.), Bioanalysis, Immunogenicity and Biomarkers (L.H., X.Z., K.D.), Integrated Biological Platform Sciences (Y.C., We.Z., J.L., J.W.), Brain Delivery Technologies (Wa.Z.), Platform Technology and Science (G.C.T.), and Department of Neuroexcitation Discovery Performance Unit (G.L., W.C., T.Y., X.Y., Z.W.), GlaxoSmithKline R&D, Shanghai, People’s Republic of China; and Department of Bioanalysis, Immunogenicity and Biomarkers, Platform Technology and Science, GlaxoSmithKline, Ware, United Kingdom (S.G.S.) Received October 10, 2017; accepted March 1, 2018 Downloaded from ABSTRACT Little is known about the impact of the blood–nerve barrier (BNB) P-glycoprotein (P-gp) and breast cancer resistance protein on drug distribution into peripheral nerves. In this study, we (BCRP) inhibitor, on the peripheral nerve and central nervous examined the peripheral nerve penetration in rats of 11 small- system (CNS) tissue penetration of imatinib.
    [Show full text]
  • DNA Interactions and Photocleavage by Anthracene, Acridine, and Carbocyanine-Based Chromophores
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry Fall 9-23-2013 DNA Interactions and Photocleavage by Anthracene, Acridine, and Carbocyanine-Based Chromophores Carla Mapp Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Mapp, Carla, "DNA Interactions and Photocleavage by Anthracene, Acridine, and Carbocyanine-Based Chromophores." Dissertation, Georgia State University, 2013. https://scholarworks.gsu.edu/chemistry_diss/82 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. DNA INTERACTIONS AND PHOTOCLEAVAGE BY ANTHRACENE, ACRIDINE, AND CARBOCYANINE-BASED CHROMOPHORES by CARLA TERRY MAPP Under the Direction of Dr. Kathryn B. Grant ABSTRACT The interaction of small molecules with DNA has been extensively studied and has produced a large catalogue of molecules that non-covalently bind to DNA though groove binding, intercalation, electrostatics, or a combination of these binding modes. Anthracene, acridine, and carbocyanine-based chromophores have been examined for their DNA binding properties and photo-reactivities. Their planar aromatic structures make them ideal chromophores that can be used to probe DNA structural interactions and binding patterns. We have studied DNA binding and photocleavgage properties of a bisacridine chromophore joined by a 2,6-bis(aminomethyl)pyridine copper-binding linker (Chapter II), a series of 9-aminomethyl anthracene chromophores (Chapters III and IV), both under conditions of high and low ionic strength, as well as a series of pentamethine linked symmetrical carbocyanine dyes (Chapter V).
    [Show full text]
  • Acridine: a Versatile Heterocyclic Nucleus
    Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 69 No. 1 pp. 3ñ9, 2012 ISSN 0001-6837 Polish Pharmaceutical Society REVIEW ACRIDINE: A VERSATILE HETEROCYCLIC NUCLEUS RAMESH KUMAR*, MANDEEP KAUR AND MEENA KUMARI Lord Shiva College of Pharmacy, Sirsa-125055, Haryana, India Abstract: Acridine is a heterocyclic nucleus. It plays an important role in various medicines. A number of ther- apeutic agents are based on acridine nucleus such as quinacrine (antimalarial), acriflavine and proflavine (anti- septics), ethacridine (abortifacient), amsacrine and nitracine (anticancer), and tacrine. Acridine is obtained from high boiling fraction of coal tar. It is also obtained in nature from plant and marine sources. Acridine undergoes a number of reactions such as nucleophilic addition, electrophilic substitution, oxidation, reduction, reductive alkylation and photoalkylation. The present review article summarizes the synthesis, reaction, literature review and pharmaceutical importance of acridine. Keywords: acridines, cytotoxic, antiseptic, antimicrobial The synthesis of acridine and analogues has 1935 and penicillin, 1944) superseded the acridine attracted considerable attention from organic and based therapy. But in present arena, massive medicinal chemists for many years, as a number of increase in drug resistance bacterial infections has natural sources have been reported to have this het- attracted the attention toward acridine once again. In erocyclic nucleus. Chemically, acridine is an alka- the literature, it has been found that acridine deriva- loid from anthracene. It is also known by the names tives possess widely differing activities such as anti- of dibenzopyridine, 2,3,5,6-dibenzopyridine and 10- inflammatory and anticancer (3), antihelmintics (4), azaanthracene. Acridine has an irritating odor. It insectecidal, rodenticidal (5), fungicidal (6) and crystallizes in colorless to light yellow needles with antitumor activities (7).
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • Substituent Effect on Aggregation Behavior and DNA Binding
    International Journal of Molecular Sciences Article Arylamine Analogs of Methylene Blue: Substituent Effect on Aggregation Behavior and DNA Binding Alena Khadieva 1, Olga Mostovaya 1, Pavel Padnya 1,* , Valeriy Kalinin 1 , Denis Grishaev 2, Dmitrii Tumakov 3 and Ivan Stoikov 1,* 1 A.M. Butlerov’ Chemistry Institute of Kazan Federal University, 18 Kremlyovskaya Str., 420008 Kazan, Russia; [email protected] (A.K.); [email protected] (O.M.); [email protected] (V.K.) 2 Scientific and Educational Center of Pharmaceutics, Kazan Federal University, 420008 Kazan, Russia; [email protected] 3 Institute of Computational Mathematics and Information Technologies, Kazan Federal University, 420008 Kazan, Russia; [email protected] * Correspondence: [email protected] (P.P.); [email protected] (I.S.); Tel.: +7-(843)-233-7241 (I.S.) Abstract: The synthesis of new phenothiazine derivatives, analogs of Methylene Blue, is of par- ticular interest in the design of new drugs, as well as in the development of a new generation of agents for photodynamic therapy. In this study, two new derivatives of phenothiazine, i.e., 3,7-bis(4-aminophenylamino)phenothiazin-5-ium chloride dihydrochloride (PTZ1) and 3,7-bis(4- sulfophenylamino)phenothiazin-5-ium chloride (PTZ2), are synthesized for the first time and char- acterized by NMR, IR spectroscopy, HRMS and elemental analysis. The interaction of the obtained compounds PTZ1 and PTZ2 with salmon sperm DNA is investigated. It is shown by UV-Vis spec- troscopy and DFT calculations that substituents in arylamine fragments play a crucial role in dimer Citation: Khadieva, A.; Mostovaya, formation and interaction with DNA.
    [Show full text]
  • Stability and Structural Features of DNA Intercalation with Ethidium Bromide, Acridine Orange and Methylene Blue
    ARTICLE IN PRESS Journal of Molecular Structure xxx (2006) xxx–xxx www.elsevier.com/locate/molstruc Stability and structural features of DNA intercalation with ethidium bromide, acridine orange and methylene blue Shohreh Nafisi a,*, Ali Akbar Saboury b, Nahid Keramat a, Jean-Francois Neault c, Heidar-Ali Tajmir-Riahi c a Deparment of Chemistry, Azad University, Central Tehran Branch, 14169 63316 Tehran, Iran b Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran c Department of Chemistry and Biology, University of Quebec at Trois-Rivieres, C.P. 500, TR, Que., Canada G9A 5H7 Received 1 March 2006; received in revised form 27 April 2006; accepted 2 May 2006 Abstract Ethidium bromide (EB), acridine orange (AO), methylene blue (MB) and other fluorescent compounds are often used to probe DNA structure in drug–DNA and protein–DNA interactions. They bind nucleic acids via intercalative mode and cause major changes to DNA and RNA structures. The aim of this study was to examine the stability and structural features of calf-thymus DNA complexes with EB, AO and MB in aqueous solution, using constant DNA concentration (12.5 mM) and various pigment/DNA(P) ratios of 1/40, 1/20, 1/ 10, 1/4 and 1/2. FTIR, UV–visible spectroscopy and isothermal titration calorimetry (ITC) are used to determine the ligand intercalation and external binding modes, the binding constant and the stability of pigment–DNA complexes in aqueous solution. Structural analysis showed major intercalation of EB, AO and MB into polynucleotides G–C and A–T base pairs with minor external binding and overall bind- 4 À1 4 À1 4 À1 ing constants of KEB = 6.58 · 10 M , KAO = 2.69 · 10 M and KMB = 2.13 ·10 M .
    [Show full text]
  • Acridine and Phenothiazine Derivatives As Pharmacotherapeutics for Prion Disease
    Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease Carsten Korth*, Barnaby C. H. May†, Fred E. Cohen*†‡§, and Stanley B. Prusiner*ʈ‡¶ *Institute for Neurodegenerative Diseases and Departments of †Cellular and Molecular Pharmacology, ‡Biochemistry and Biophysics, §Medicine, and ¶Neurology, University of California, San Francisco, CA 94143 Contributed by Stanley B. Prusiner, June 1, 2001 Prion diseases in humans and animals are invariably fatal. Prions hibit PrPSc formation, including Congo red, have been identified are composed of a disease-causing isoform (PrPSc) of the normal by using scrapie-infected cultured cells (19–21). Some of these host prion protein (PrPC) and replicate by stimulating the conver- compounds have been examined in rodents but none have been sion of PrPC into nascent PrPSc. We report here that tricyclic effective when given around the time that neurologic signs derivatives of acridine and phenothiazine exhibit half-maximal appear (22). Sc inhibition of PrP formation at effective concentrations (EC50) In a search for compounds that might prove effective in between 0.3 ␮M and 3 ␮M in cultured cells chronically infected treating prion diseases, we have used scrapie-infected neuro- ␮ with prions. The EC50 for chlorpromazine was 3 M, whereas blastoma (ScN2a) cells to screen for inhibition of nascent PrPSc quinacrine was 10 times more potent. A variety of 9-substituted, formation as well as the clearance of preexisting PrPSc. Based on acridine-based analogues of quinacrine were synthesized, which the demonstration that PrPSc formation occurs in cholesterol- demonstrated variable antiprion potencies similar to those of rich microdomains, inhibitors of cholesterol biosynthesis were chlorpromazine and emphasized the importance of the side chain examined for their ability to inhibit the conversion of PrPC into in mediating the inhibition of PrPSc formation.
    [Show full text]